
- /
- Supported exchanges
- / US
- / BCAX.NASDAQ
Bicara Therapeutics Inc. Common Stock (BCAX NASDAQ) stock market data APIs
Bicara Therapeutics Inc. Common Stock Financial Data Overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Bicara Therapeutics Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bicara Therapeutics Inc. Common Stock data using free add-ons & libraries
Get Bicara Therapeutics Inc. Common Stock Fundamental Data
Bicara Therapeutics Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -121 003 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.5367
Get Bicara Therapeutics Inc. Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bicara Therapeutics Inc. Common Stock News

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves
The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quart...


Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...

Genmab reportedly nearing deal to acquire cancer drug developer Merus
[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Danish biotech Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) is in advanced discussions to acquire Merus...

Bicara Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.